Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age ≤35)

Göksu, Sema Sezgin; Taştekin, Didem; Arslan, Deniz; Gündüz, Şeyda; Tatlı, Ali Murat; Ünal, Dilek; Salim, Derya Kivrak; Güler, Tunç; Çoşkun, Hasan Şenol

doi:10.7314/apjcp.2014.15.16.6665

Cited by 20 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BCS has been shown to provide local control similar to mastectomy in young patients (18). Nevertheless, it has been published that the most frequently performed surgical procedure for breast cancer in patients under 35 years of age was mastectomy (19). The mastectomy rate in our study was found to be higher in young patients as compared to the postmenopausal group.…”

Section: Discussionmentioning

confidence: 40%

“…In our study, significantly higher rates of grade 3 tumors and Ki-67 rates were identified in the younger patients. Göksu et al (19) reported that luminal B was the most common molecular subtype in breast cancer patients 35 years of age and younger. In addition,triple negative breast cancer rates have been reported to be high in this group of patients.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that younger patients are diagnosed at more advanced stages due to lack of screening mammography, dense breast parenchymal structure, and low awareness of patients (19,23,25). Reviews indicating that younger patients present with advanced staged breast cancer have also been published (26).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age

Emiroğlu¹,

Karaalı²,

Sert³

et al. 2015

J Breasth Health

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate the clinical, pathologic and management differences between breast cancer patients under 35 years of age and postmenopausal patients above 55 years of age. Materials and Methods:Patients who were operated on for breast cancer between November 2003 and March 2013 in our hospital were retrospectively analyzed. Patients were separated into two Groups according their age; Group 1 (<35 years) and Group 2 (>55 years).Results: 94 patients with breast cancer, 45 patients in Group 1 and 49 patients in Group 2, were included in the study. The mean follow-up was 51 (19-121) months and 50 (19-120) months in Groups 1 and 2, respectively. Stages of breast cancer at the time of diagnosis were similar between the two groups. The groups were similar in terms of rates of re-excision (p=0.42), local recurrence (p=0.34) and solid organ metastases (p=0.182). The number of oncoplastic and reconstructive procedures were higher in Group 1 (p=0.04). Regarding pathological results, the rate of grade 3 tumors, those with Ki-67>12 and triple negative breast cancer were found to be higher in Group 1. In addition, the number of patients receiving chemotherapy was significantly higher in Group 1 (p=0.03). Conclusion:Oncologic results were similar between young patients and postmenopausal patients. Nevertheless, tumor biology was found to be worse in young patients. In addition, oncoplastic and reconstructive approaches were significantly higher in young patients.

show abstract

Section: Discussionmentioning

confidence: 40%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age

Emiroğlu¹,

Karaalı²,

Sert³

et al. 2015

J Breasth Health

View full text Add to dashboard Cite

show abstract

“…(16) ise genç yaş grubunda yapılan cerrahi tipinin prognozda etkili olmadığını vurgulamış-lardır. Meme kanserinin tedavisinde yaş MKC için bir kontraendikasyon değildir (17) . Genç hasta grubunda MKC'nin mastektomi kadar yerel kontrol sağladı-ğı gösterilmiştir (18) .…”

Section: Discussionunclassified

“…Göksu ve ark. 'nın (17) yaptığı çalışmalarda, 35 yaş ve altı meme kanserli hastalarda Luminal B'nin en sık görülen moleküler alt tip olduğu yayınlandı. Benzer şekilde Collins ve ark.…”

Section: Discussionunclassified

Evaluation of patients with breast cancer 40 years of age and under and 70 years of age and older

Üreyen¹,

İlhan²,

Dadalı³

et al. 2016

Terh

View full text Add to dashboard Cite

ÖZAmaç: Çalışmadaki amacımız kırk yaş ve altı ile yetmiş yaş ve üstü meme kanserli hastaların klinik ve histopatolojik özellikler ile tedavi yaklaşımlarını karşılaştırmak ve prognostik faktörler açısından yaşa göre farklılık olup olmadığını incelemektir. Yöntem: Kliniğimizde invaziv meme karsinomu nedeniyle ameliyat edilen 40 yaş ve altı (Grup I) ile 70 yaş ve üstü (Grup II) hastalar retrospektif olarak tümör histopatoloji tipi, uygulanan cerrahi, aksiler tutulum ve prognostik parametreler yönünden irdelendi. Bulgular: Grup I'de 15 (%55,6), Grup II'de 12 (%44,6) meme kanserli hasta çalışma-ya dâhil edildi. Grup I'de 7 (%46) ve Grup II'de 2 (%16)) hastaya meme koruyucu cerrahi (MKC) uygulandı. Operasyon tipinin grup içi karşılaştırılmasında Grup II olgularının ameliyat tipinde anlamlı farklı bulundu (p=0,021). Gruplar arasında histopatoloji sonucu açısından anlamlı fark bulunmamış (p>0,05) olup, grup içi karşılaş-tırılmasında Grup I hastalarının histopatoloji sonucunda anlamlı farklı bulundu (p=0,001). Erken ve lokal ileri evre açısından Grup I ve Grup II arasında sırasıyla %66,7'ye karşın %33,3 oranında erken evreye rastlandı. Gruplar içi karşılaştırmada Grup II olgularının, ER pozitifliği, PR pozitifliği ve moleküler altgrup sınıflaması dağılımları beklenen dağılımlardan anlamlı farklı bulundu (p<0,05). Sonuç: Genç yaş ve ileri yaş meme kanserlerinde benzer prognostik faktörlerin varlı-ğının yanı sıra her bir grup kendine özgün iyi ya da kötü prognostik faktörlere sahip olabilir.Anahtar kelimeler: Meme kanseri, genç yaş, ileri yaş, prognostif faktör ABSTRACT Objective: The aim of our study is to compare clinicopathological features; and treatment approaches, and investigate if any age-related difference exists in prognostic factors between breast cancer patients aged ≤ 40, and ≥ 70 years. Methods: Patients aged ≤ 40 (Group 1) and ≥ 70 years (Group 2) who had surgical intervention for invasive breast carcinoma were evaluated retrospectively in terms of histological type, surgical procedure, axillary involvement and prognostic parameters. Results: Fifteen (55.6%) patients in Group 1 and 12 (44.6%) in Group 2 were included in the study Breast-conserving surgery was performed for 7 (46%) patients in Group 1 and 2 (16%) patients in Group 2. In intergroup comparison of groups, a statistically significant difference was found in Group 2 in terms of operation type (p=0.021).There were no significant difference between groups in terms of histopathological results (p>0.05), however, intragroup comparisons of the results in Group 1 yielded significant differences (p=0.001). Early, and locally advanced disease stages were detected in 66,7% of Group 1 and 33,3% of Group 2 patients. There were significant intragroup differences in Group 2 patients, in terms of ER, and PR positivity and molecular subtypes (p<0.05). Conclusion: Younger, and advanced age patients with breast cancer may have similar prognostic factors, while each group may have unique prognostic parametres.

show abstract

Fusion‐associatedcarcinomas of the breast: Diagnostic, prognostic, and therapeutic significance

Loo

Yates

Yang

et al. 2022

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Recurrent gene fusions comprise a class of viable genetic targets in solid tumors that have culminated several recent breakthrough cancer therapies. Their role in breast cancer, however, remains largely underappreciated due to the complexity of genomic rearrangements in breast malignancy. Just recently, we and others have identified several recurrent gene fusions in breast cancer with important clinical and biological implications. Examples of the most significant recurrent gene fusions to date include (1) ESR1::CCDC170 gene fusions in luminal B and endocrine‐resistant breast cancer that exert oncogenic function via modulating the HER2/HER3/SRC Proto‐Oncogene (SRC) complex, (2) ESR1 exon 6 fusions in metastatic disease that drive estrogen‐independent estrogen‐receptor transcriptional activity, (3) BCL2L14::ETV6 fusions in a more aggressive form of the triple‐negative subtype that prime epithelial–mesenchymal transition and endow paclitaxel resistance, (4) the ETV6::NTRK3 fusion in secretory breast carcinoma that constitutively activates NTRK3 kinase, (5) the oncogenic MYB‐NFIB fusion as a genetic driver underpinning adenoid cystic carcinomas of the breast that activates MYB Proto‐Oncogene (MYB) pathway, and (6) the NOTCH/microtubule‐associated serine–threonine (MAST) kinase gene fusions that activate NOTCH and MAST signaling. Importantly, these fusions are enriched in more aggressive and lethal breast cancer presentations and appear to confer therapeutic resistance. Thus, these gene fusions could be utilized as genetic biomarkers to identify patients who require more intensive treatment and surveillance. In addition, kinase fusions are currently being evaluated in breast cancer clinical trials and ongoing mechanistic investigation is exposing therapeutic vulnerabilities in patients with fusion‐positive disease.

show abstract

Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age ≤35)

Cited by 20 publications

References 30 publications

Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age

Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age

Evaluation of patients with breast cancer 40 years of age and under and 70 years of age and older

Fusion‐associatedcarcinomas of the breast: Diagnostic, prognostic, and therapeutic significance

Contact Info

Product

Resources

About